MedPath

BAYER AG

BAYER AG logo
🇩🇪Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com
Clinical Trials
Related News

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

Phase 3
Completed
Conditions
Venous Thromboembolism
Interventions
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Standard of Care
First Posted Date
2014-09-09
Last Posted Date
2020-04-01
Lead Sponsor
Bayer
Target Recruit Count
500
Registration Number
NCT02234843

Naproxen Sodium/ASA Platelet Study

Phase 1
Completed
Conditions
Hematology
Interventions
Drug: Naproxen Sodium (Aleve, BAY117031)
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
First Posted Date
2014-09-01
Last Posted Date
2016-07-15
Lead Sponsor
Bayer
Target Recruit Count
117
Registration Number
NCT02229461

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration

Phase 2
Terminated
Conditions
Macular Degeneration
Interventions
Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506)
Drug: Ranibizumab
Procedure: Sham IVT
Drug: Placebo
First Posted Date
2014-08-21
Last Posted Date
2016-09-08
Lead Sponsor
Bayer
Target Recruit Count
52
Registration Number
NCT02222207

First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784

Phase 1
Completed
Conditions
Clinical Trials, Phase I as Topic
Interventions
Drug: BAY1214784
Drug: Placebo
First Posted Date
2014-08-08
Last Posted Date
2015-03-11
Lead Sponsor
Bayer
Target Recruit Count
48
Registration Number
NCT02212080

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy

Completed
Conditions
Pulmonary Embolism (PE)
Deep Vein Thrombosis (DVT)
Interventions
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Recommended VTE pharmacological treatments according to international guidelines
First Posted Date
2014-08-07
Last Posted Date
2019-08-29
Lead Sponsor
Bayer
Target Recruit Count
1987
Registration Number
NCT02210819

Bay98-7196, Dose Finding / POC Study

Phase 2
Completed
Conditions
Endometriosis
Interventions
Drug: Placebo
Drug: Lupron / Leuprolide acetate
Drug: Levonorgestrel
Drug: Anastrozole
First Posted Date
2014-07-29
Last Posted Date
2023-11-07
Lead Sponsor
Bayer
Target Recruit Count
319
Registration Number
NCT02203331

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Phase 3
Completed
Conditions
Castration-Resistant
Prostate Cancer Non-Metastatic
Interventions
Drug: Placebo
Drug: Darolutamide (Nubeqa, BAY1841788)
First Posted Date
2014-07-25
Last Posted Date
2022-06-28
Lead Sponsor
Bayer
Target Recruit Count
1509
Registration Number
NCT02200614

Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

Phase 4
Completed
Conditions
Hypertension, Pulmonary
Interventions
Drug: Riociguat (Adempas, BAY63-2521)
First Posted Date
2014-07-16
Last Posted Date
2017-10-13
Lead Sponsor
Bayer
Target Recruit Count
75
Registration Number
NCT02191137

Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib

Active, not recruiting
Conditions
Thyroid Carcinoma
Interventions
Drug: Sorafenib (Nexavar, BAY43-9006)
First Posted Date
2014-07-09
Last Posted Date
2024-12-20
Lead Sponsor
Bayer
Target Recruit Count
453
Registration Number
NCT02185560

Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol

Phase 1
Completed
Conditions
Pharmacokinetics
Interventions
Drug: Microgynon
Drug: Noristerat(BAY86-6308)
First Posted Date
2014-06-23
Last Posted Date
2016-02-18
Lead Sponsor
Bayer
Target Recruit Count
16
Registration Number
NCT02170038
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy